drugset
drugset / Trial / NCT07244380

Phase II Trial of S101 Autologous Anti-CD7 CAR-T Cells in Patients With R/R T-LBL/ALL.

NCT07244380 ↗

Phase 2 Not yet recruiting 38 enrolled Hebei Senlang Biotechnology Inc., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To Evaluate the Efficacy and safety of S101 for Treating CD7-Positive Relapsed or Refractory T-LBL/ALL.

Timeline

Start
2025-11-28
Primary completion
2026-09-30
Completion
2028-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject S101 Cell therapy 2e+06 cells/kg Intravenous

Indications

T lymphoblastic leukemia/lymphoma